Peripheral T-Cell Lymphoma: FDA Updates

November 16, 2018 – The U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and other CD30-expressing peripheral T-cell lymphoma (PTCL). This is the first FDA approved frontline treatment for PTCL.  More information.

November 9, 2017 – The U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.  More information.

March 30, 2016 – The U.S. Food and Drug Administration approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). More information.

January 27, 2015 – The U.S. Food and Drug Administration (FDA) approved a same-day delivery device for pegfilgrastim (Neulasta) for non-Hodgkin lymphoma patients who do not need to return to the clinic the day after chemotherapy. More Information.

June 3, 2014 – The U.S. Food and Drug Administration approved belinostat (Beleodaq) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). More Information.

August 19, 2011 – The U.S. Food and Drug Administration approved brentuximab vedotin (Adcetris) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).  More Information.

June 16, 2011 – The U.S. Food and Drug Administration approved romidepsin (Istodax) as a treatment for people with PTCL who have received at least one prior therapy. More Information.

September 25, 2009 – The U.S. Food and Drug Administration approved pralatrexate (Folotyn) for the treatment of patients with relapsed or refractory PTCL. More Information.